BMC Psychiatry
November 29, 2019
Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis et al.
A triple-blind randomized placebo-controlled trial investigates daily oral esketamine versus placebo as an add-on to regular antidepressants in patients with treatment-resistant depression over 6 weeks, followed by a 4-week follow-up. This is the first such trial to examine the efficacy, safety, tolerability, mechanisms of action, and economic impact of repeated oral esketamine administration. If effective and tolerated, oral esketamine offers practical advantages over intravenous administration. The study aims to address the urgent need for additional treatment strategies for treatment-resistant depression.
BMC Psychiatry
October 11, 2019
People with nightmare disorder report more frequent and intense nightmares and poorer family relationships compared to healthy volunteers. The findings suggest a link between nightmare frequency and the quality of family interactions, with nightmare disorder patients experiencing greater relational difficulties.
BMC Psychiatry
November 9, 2015
M. Cladder-Micus, J. Vrijsen, E. Becker et al.
A randomized controlled trial will compare Mindfulness-Based Cognitive Therapy (MBCT) plus treatment-as-usual (TAU) against TAU alone for patients with chronic, treatment-resistant depression who have already received antidepressant medication and either cognitive behavioral therapy or interpersonal therapy. The primary outcome is depressive symptoms; secondary outcomes include remission rates, quality of life, rumination, mindfulness skills, and self-compassion. Assessments occur at baseline and after the intervention or TAU period, with follow-up at three and six months post-MBCT for completers. The trial aims to provide information on MBCT's effectiveness in this population.
BMC Psychiatry
March 12, 2013
Shawyer Frances, N Meadows Graham, Judd Fiona et al.
Mindfulness-based cognitive therapy (MBCT) is a group intervention that reduces depressive relapse in people with a history of major depression. This trial tests MBCT under real-world conditions, comparing it to a self-monitoring control (Depression Relapse Active Monitoring, DRAM) in 204 participants recruited from primary and secondary care who have had three or more prior episodes but are currently well. Follow-up lasts two years. The study also examines health economics, comorbidity effects, and mechanisms of action. Results will inform whether MBCT should be recommended and funded for depression treatment in Australia and elsewhere.
BMC Psychiatry
March 12, 2013
YS Wong Samuel, WS Mak Winnie, YL Cheung Eliza et al.
An eight-week Mindfulness-Based Cognitive Therapy (MBCT) program may reduce anxiety symptoms in people with generalized anxiety disorder. A proposed three-armed randomized controlled trial will compare MBCT plus usual care, a psycho-education program plus usual care, and usual care alone. 228 participants diagnosed with generalized anxiety disorder via the Structured Clinical Interview for DSM-IV will be recruited from community clinics. The primary outcome is change in anxiety and worry scores from baseline to the end of the intervention, measured by the Beck Anxiety Inventory and Penn State Worry Scale. This is the first trial to compare MBCT with an active control group.
BMC Psychiatry
April 30, 2010
S Duggan Danielle, J Whitaker Chris, Russell Daphne et al.
Relapse rates for recurrent depression range from 50-80%, and the risk is especially high for people who become suicidal when depressed. This trial compares Mindfulness-Based Cognitive Therapy (MBCT), which combines mindfulness meditation with cognitive therapy, against Cognitive Psycho-Education (CPE), a cognitive treatment without meditation, and treatment as usual (TAU). Participants with recurrent depression are randomly assigned to MBCT plus TAU, CPE plus TAU, or TAU alone in a 2:2:1 ratio, with a target of 300 participants after attrition. Both active treatments are delivered in weekly two-hour group sessions for eight weeks. Effects on relapse and suicidal symptoms will be measured over 12 months, with assessments immediately after treatment and at three, six, nine, and twelve months.
BMC Psychiatry
December 1, 2005
Bernard Favrat, Annick Ménétrey, Marc Augsburger et al.
Two healthy, occasional but regular cannabis users with no psychiatric history experienced transient psychotic symptoms—depersonalization, paranoid feelings, and derealization—after taking oral cannabis under controlled experimental conditions. Unlike most case reports, blood levels and timing were documented, and all subjects tested negative for other drugs and alcohol. Although oral administration produces limited blood concentrations, it can still trigger significant psychotic reactions.